BNTX ▼ -1.4% - BioNTech SE
$BNTX - BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
25-OCT-2026 03:30 AM ET
Share this post
More filings for $BNTX
BNTX ▼ -0.7% - BioNTech SEOct 22, 2026BNTX ▲ +0.4% - BioNTech SEOct 20, 2026BNTX ▲ +0.2% - BioNTech SEOct 19, 2026BNTX ▼ -1.2% - BioNTech SEOct 13, 2026BNTX ▲ +3.4% - BioNTech SESep 14, 2026BNTX ▼ -7.2% - BioNTech SEAug 28, 2026
View full $BNTX filing history →💬 Comments
Loading comments…
Leave a comment